Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study (2022)
- Authors:
- Aikawa, Nadia E
- Kupa, Leonard de Vinci Kanda
- Pasoto, Sandra Gofinet
- Shinjo, Samuel Katsuyuki
- Pereira, Rosa Maria Rodrigues
- Sartori, Ana Marli Christovam
- Duarte, Alberto José da Silva
- Antonangelo, Leila
- Sabino, Ester Cerdeira
- Menezes, Paulo Rossi
- Kallas, Esper Georges
- Silva, Clovis Artur Almeida da
- Bonfa, Eloisa Silva Dutra de Oliveira
- USP affiliated authors: KUPA, LEONARD DE VINCI KANDA - FM ; SHINJO, SAMUEL KATSUYUKI - FM ; PEREIRA, ROSA MARIA RODRIGUES - FM ; SARTORI, ANA MARLI CHRISTOVAM - FM ; DUARTE, ALBERTO JOSE DA SILVA - FM ; ANTONANGELO, LEILA - FM ; SABINO, ESTER CERDEIRA - FM ; MENEZES, PAULO ROSSI - FM ; KALLAS, ESPER GEORGES - FM ; SILVA, CLOVIS ARTUR ALMEIDA DA - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
- Unidade: FM
- DOI: 10.1016/S2665-9913(21)00327-1
- Subjects: IMUNOGENÉTICA; COVID-19; SISTEMA IMUNE; IMUNOGENICIDADE DA VACINA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Lancet rheumatology
- ISSN: 2665-9913
- Volume/Número/Paginação/Ano: v. 4, n. 2, p. E113-E124, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: other-oa
-
ABNT
AIKAWA, Nadia E et al. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet rheumatology, v. 4, n. 2, p. E113-E124, 2022Tradução . . Disponível em: https://doi.org/10.1016/S2665-9913(21)00327-1. Acesso em: 05 out. 2024. -
APA
Aikawa, N. E., Kupa, L. de V. K., Pasoto, S. G., Shinjo, S. K., Pereira, R. M. R., Sartori, A. M. C., et al. (2022). Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet rheumatology, 4( 2), E113-E124. doi:10.1016/S2665-9913(21)00327-1 -
NLM
Aikawa NE, Kupa L de VK, Pasoto SG, Shinjo SK, Pereira RMR, Sartori AMC, Duarte AJ da S, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CAA da, Bonfa ESD de O. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [Internet]. Lancet rheumatology. 2022 ; 4( 2): E113-E124.[citado 2024 out. 05 ] Available from: https://doi.org/10.1016/S2665-9913(21)00327-1 -
Vancouver
Aikawa NE, Kupa L de VK, Pasoto SG, Shinjo SK, Pereira RMR, Sartori AMC, Duarte AJ da S, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CAA da, Bonfa ESD de O. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [Internet]. Lancet rheumatology. 2022 ; 4( 2): E113-E124.[citado 2024 out. 05 ] Available from: https://doi.org/10.1016/S2665-9913(21)00327-1 - Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
- Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
- Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
- SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy
- Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring
- Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus
- Reduced ovarian reserve in patients with adult polymyositis
- Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases
- Subclinical Reduced Ovarian Reserve in Adult Polymiositis Patients
Informações sobre o DOI: 10.1016/S2665-9913(21)00327-1 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas